期刊
NATURE REVIEWS DRUG DISCOVERY
卷 17, 期 12, 页码 865-886出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2018.174
关键词
-
资金
- UK Medical Research Council (MRC) [MC_U105663142]
- Wellcome Trust [110159/Z/15/Z, 110158/Z/15/Z]
- MRC [MC_UU_00015/3] Funding Source: UKRI
Although the development of mitochondrial therapies has largely focused on diseases caused by mutations in mitochondrial DNA or in nuclear genes encoding mitochondrial proteins, it has been found that mitochondrial dysfunction also contributes to the pathology of many common disorders, including neurodegeneration, metabolic disease, heart failure, ischaemia-reperfusion injury and protozoal infections. Mitochondria therefore represent an important drug target for these highly prevalent diseases. Several strategies aimed at therapeutically restoring mitochondrial function are emerging, and a small number of agents have entered clinical trials. This Review discusses the opportunities and challenges faced for the further development of mitochondrial pharmacology for common pathologies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据